Target Price | $39.77 |
Price | $30.91 |
Potential |
28.66%
register free of charge
|
Number of Estimates | 13 |
13 Analysts have issued a price target Denali Therapeutics Inc. 2025 .
The average Denali Therapeutics Inc. target price is $39.77.
This is
28.66%
register free of charge
$90.00
191.17%
register free of charge
$22.00
28.83%
register free of charge
|
|
A rating was issued by 15 analysts: 14 Analysts recommend Denali Therapeutics Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Denali Therapeutics Inc. stock has an average upside potential 2025 of
28.66%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Million $ | 330.53 | 17.93 |
204.75% | 94.58% | |
EBITDA Margin | -54.45% | -2,572.59% |
82.30% | 4,624.78% | |
Net Margin | -45.90% | -2,027.18% |
86.62% | 4,316.69% |
14 Analysts have issued a sales forecast Denali Therapeutics Inc. 2024 . The average Denali Therapeutics Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Denali Therapeutics Inc. EBITDA forecast 2024. The average Denali Therapeutics Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Denali Therapeutics Inc. Analysts have issued a net profit forecast 2024. The average Denali Therapeutics Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.06 | -2.54 |
59.23% | 139.62% | |
P/E | negative | |
EV/Sales | 199.57 |
14 Analysts have issued a Denali Therapeutics Inc. forecast for earnings per share. The average Denali Therapeutics Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Denali Therapeutics Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Denali Therapeutics Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.